The companies are developing a blood-based assay for differentiating lung cancer from benign disease in patients testing positive in low-dose CT screens.
Though the pace of Quest's acquisitions has slowed this year, the latest deal with BCL continues a string of activities resulting from the implementation of PAMA.
In the long term, the company is developing a plan to create more tests based on its technology, which digitizes blood samples and turns them into images.
The firm is offering total consideration of $1,018.36 per $1,000 for notes tendered by Dec. 2, which includes an early tender premium of $30 per $1,000.
The firm said that its panel enables receipt of results for life-threatening conditions, such as sepsis and bacteremia, within about 11 minutes at the point of care.
Veracyte has also acquired Nanostring's Prosigna breast cancer and LymphMark lymphoma assays and plans to develop diagnostic tests using the nCounter platform.
The LCD will provide coverage for the Decipher Prostate Biopsy genomic test for men with both favorable and unfavorable intermediate-risk prostate cancer.
ArcherDx will develop in vitro diagnostic tests, including companion diagnostics, to run on Illumina's NextSeq 550Dx next-generation sequencing system.
